(Stroke. 2001;32:1481.)
© 2001 American Heart Association, Inc.
Original Contributions |
From the Departments of Neurology (Y.S-N., T.U., N.H., Y.M.) and Cardiology (Y.W.), Juntendo University School of Medicine, Tokyo; Department of Neurology, Tokyo Metropolitan Ebara Hospital (T.N., M.Y.); and Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (M.H.) (Japan).
Correspondence to Takao Urabe, MD, Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail t_urabe{at}med.juntendo.ac.jp
Background and PurposeLipid and lipoprotein abnormalities have been implicated in the pathogenesis of ischemic cerebrovascular disease and atherosclerosis. Lipoprotein lipase (LPL) plays an important role in plasma lipoprotein metabolism. Several studies have recently reported the presence of a relationship between Ser447Stop mutation of LPL and coronary artery disease. Other polymorphisms (HindIII and PvuII) of the LPL gene have already been shown to correlate significantly with dyslipidemia. We investigated whether these polymorphisms are associated with increased risk of ischemic cerebrovascular disease (CVD).
MethodsWe recruited 177 CVD patients (atherothrombotic infarction, n=71; cardioembolic infarction, n=30; lacunar infarction, n=76) and 177 healthy control subjects. Subjects were genotyped for the Ser447Stop mutation and for HindIII/PvuII restriction fragment length polymorphisms of the LPL gene, and the findings were investigated for associations with the clinical subtypes of CVD and with lipid levels.
ResultsThe Ser447Stop mutation correlated significantly with CVD (0.107 versus 0.158; P=0.035). For the CG+GG versus CC genotype, the odds ratio between control subjects and CVD patients with atherothrombotic infarction was 0.42 (95% CI, 0.18 to 0.99) (P=0.046). Serum HDL cholesterol and triglyceride levels did not correlate significantly with the Ser447Stop genotype. HindIII polymorphism correlated significantly with CVD (0.234 versus 0.169; P=0.031), but the frequency of PvuII polymorphism was not significantly different between groups.
ConclusionsOur results suggest that the Ser447Stop mutation of the LPL gene is a novel genetic marker for low risk of atherothrombotic cerebral infarction.
Key Words: atherosclerosis cerebral infarction lipids polymorphism risk factors
This article has been cited by other articles:
![]() |
J. Rip, M. C. Nierman, C. J. Ross, J. W. Jukema, M. R. Hayden, J. J.P. Kastelein, E. S.G. Stroes, and J. A. Kuivenhoven Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1236 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Hegele, C. J.D. Ross, J. Twisk, J. A. Kuivenhoven, J. Rip, J. J. Kastelein, and M. R. Hayden Gene therapy with lipoprotein lipase variant S447X. Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): e25 - e25. [Full Text] [PDF] |
||||
![]() |
J. Rip, M. C. Nierman, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, J. N.I. van Miert, B. A. Hutten, J. J.P. Kastelein, J. A. Kuivenhoven, et al. Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 637 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Spence, M. R. Ban, and R. A. Hegele Lipoprotein Lipase (LPL) Gene Variation and Progression of Carotid Artery Plaque Stroke, May 1, 2003; 34(5): 1176 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Meschia Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research Stroke, December 1, 2002; 33(12): 2770 - 2774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Levine and B. M. Coull Potassium depletion as a risk factor for stroke: Will a banana a day keep your stroke away? Neurology, August 13, 2002; 59(3): 302 - 303. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |